Charles Schwab Investment Management Inc. Acquires 125,620 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Charles Schwab Investment Management Inc. lifted its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 15.3% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 944,282 shares of the life sciences company's stock after acquiring an additional 125,620 shares during the period. Charles Schwab Investment Management Inc. owned approximately 1.22% of Integra LifeSciences worth $17,158,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Intech Investment Management LLC acquired a new stake in Integra LifeSciences in the 3rd quarter valued at $235,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Integra LifeSciences during the third quarter worth about $4,271,000. Quest Partners LLC acquired a new position in Integra LifeSciences during the 3rd quarter worth $255,000. KBC Group NV raised its holdings in shares of Integra LifeSciences by 65.2% in the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company's stock valued at $52,000 after purchasing an additional 1,120 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in Integra LifeSciences during the third quarter worth approximately $960,000. 84.78% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Michael J. Mcbreen sold 1,700 shares of the company's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the transaction, the executive vice president now owns 56,182 shares in the company, valued at $1,357,357.12. This represents a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 3.10% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

IART has been the topic of several research reports. Citigroup raised their price objective on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a "sell" rating in a research report on Tuesday, November 5th. Bank of America cut their price objective on shares of Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating for the company in a research report on Monday, October 7th. Truist Financial cut their target price on Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating on the stock in a research report on Monday, October 14th. Morgan Stanley initiated coverage on shares of Integra LifeSciences in a report on Monday, December 2nd. They set an "underweight" rating and a $20.00 target price on the stock. Finally, BTIG Research raised shares of Integra LifeSciences from a "sell" rating to a "neutral" rating in a research report on Monday, October 7th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $23.00.

Integra LifeSciences Stock Up 1.0 %

IART traded up $0.24 during midday trading on Friday, hitting $24.10. 415,162 shares of the company's stock traded hands, compared to its average volume of 789,292. Integra LifeSciences Holdings Co. has a one year low of $16.81 and a one year high of $45.42. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The company has a market cap of $1.86 billion, a PE ratio of -267.75, a price-to-earnings-growth ratio of 0.82 and a beta of 1.15. The stock's fifty day simple moving average is $21.44 and its 200-day simple moving average is $23.85.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.02. The company had revenue of $380.80 million during the quarter, compared to analyst estimates of $375.81 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company's revenue for the quarter was down .4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.76 EPS. As a group, equities analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.